GlassScriptPhysician profile
Kerry Hyman
NPI 1770019457
$10,282.96
in general payments reported to CMS, 2019-2025
23 companies · $3,229 in 2025
The $3,229 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,591 · 2020: $288 · 2021: $264 · 2022: $1,195 · 2023: $877 · 2024: $838 · 2025: $3,229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,094 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,093.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $850.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $3,180.18 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,876.54 | 2022-2025 | Infuse, Miebo, Xiidra |
| Lumenis Be INC | $960.74 | 2025 | M22 |
| Coopervision INC. | $635.30 | 2019-2025 | Misight Contact Lens, Myday Contact Lens |
| Harrow Eye, LLC | $559.72 | 2024-2025 | Vevye, Triesence |
| Abbvie INC. | $533.71 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $458.17 | 2019-2021 | |
| Alcon Vision LLC | $435.99 | 2019-2025 | Centurion, Unity, Tryptyr |
| Allergan, INC. | $375.86 | 2019-2022 | |
| Rxsight INC | $242.83 | 2022-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
| Dompe US, INC. | $236.87 | 2024-2025 | Oxervate |
| Novartis Pharmaceuticals Corporation | $154.66 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $125.81 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $109.58 | 2019 | |
| Oyster Point Pharma, INC. | $98.08 | 2022-2024 | Tyrvaya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $59.66 | 2025 | |
| Horizon Therapeutics Plc | $53.25 | 2023 | Tepezza |
| Optovue, INC. | $49.62 | 2021 | |
| Kala Pharmaceuticals, INC. | $44.84 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $28.86 | 2024 | Xdemvy |
| Lombart Brothers, INC. | $28.11 | 2025 | Opd-III |
| Shire North American Group INC | $17.34 | 2019 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerry Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.